PROS1 and COVID-19: As can beseen from the results of the analysis of the status of vaccinesthat have been registered and prepared by developers for use(see the Table), the current market for COVID-19 vaccinesincludes both classical vaccines based on the presentation ofantigens of inactivated viruses to the immune system (Gao etal., 2020) and mRNA vaccines, in which the mRNA encodingthe S protein is packaged in a lipid envelope.